Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Ran Nussbaum is the co-founder and Managing Partner of Pontifax Venture Capital, an Israeli life sciences venture capital firm. He has been instrumental in managing the firm's funds, which have invested in numerous global companies, with many achieving public listings or significant acquisitions in the biotech sector. Prior to co-founding Pontifax in 2004, he held senior management positions in Israeli financial institutions and served as CEO of Biomedix. He actively provides strategic and business development oversight to early-stage and growth-stage biopharmaceutical and healthcare technology ventures, and serves on the boards of several portfolio companies.
Portfolio
No portfolio companies in this dataset yet.
Investment activity
Portfolio by sector
Health Tech & Life Sciences1
Q&A
- What is Ran Nussbaum's primary investment focus by sector?
- Ran Nussbaum primarily focuses on the Health Tech & Life Sciences sector, with all recorded portfolio companies and investment rounds falling within this area.
- Can you name a notable portfolio company for Ran Nussbaum?
- A notable portfolio company for Ran Nussbaum is Panaxia, which operates in the medical cannabis products space.
- What type of funding rounds has Ran Nussbaum participated in?
- Ran Nussbaum has participated in PIPE (Private Investment in Public Equity) funding rounds.
- When was Ran Nussbaum's most recent investment activity?
- Ran Nussbaum's most recent recorded investment activity was in April 2020.
- What is the typical investment range for Ran Nussbaum?
- Ran Nussbaum's investment range is between $6.3M and $6.3M.
- What is the status of Panaxia, a company in Ran Nussbaum's portfolio?
- Panaxia, a company in Ran Nussbaum's portfolio, is currently public and has raised $11.6M.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2004 |
|---|